Optimal time for pharmacological treatment of abdominal aortic aneurysm

Yasunori Iida, Shigeharu Sawa, Hideyuki Shimizu

Research output: Contribution to journalReview article

Abstract

Background: Abdominal aortic aneurysm (AAA), if left untreated, poses the main risks of progressive expansion, rupture, and hemorrhage, leading to death. Large AAA with a risk of rupture is usually treated by graft replacement or endovascular aneurysm repair. Nonsurgical treatment is not an alternative for large AAA, but is potentially beneficial for small AAA which usually requires a watchful waiting approach with medication. Objective: We introduce current clinical research regarding the pharmacological treatment of small AAA and assess the optimal time for starting the treatment. Results: Data from current clinical researches on pharmacological treatment of AAA investigating the efficacy of pharmacological treatment to limit AAA growth were presented and introduced the medicines currently evaluated by randomized controlled trials for their efficacy for AAA. Conclusion: The optimal time to administer pharmacological treatment for AAA is during the stage wherein its diameter is still small. To detect early small-diameter AAA, screening tests are mandatory in high-risk patients. For pharmacological treatment, the drug that shows acceptable results in clinical tests and is the most effective for the patient’s condition should be carefully selected. Lifestyle changes should also accompany pharmacological treatment.

Original languageEnglish
Pages (from-to)1297-1301
Number of pages5
JournalCurrent Drug Targets
Volume19
Issue number11
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Abdominal Aortic Aneurysm
Pharmacology
Grafts
Medicine
Screening
Repair
Therapeutics
Rupture
Pharmaceutical Preparations
Mandatory Testing
Watchful Waiting
Research
Aneurysm
Life Style
Randomized Controlled Trials
Hemorrhage
Transplants

Keywords

  • Abdominal aortic aneurysm
  • Cardiovascular surgery
  • Chronic inflammation
  • Endovascular aneurysm repair
  • Graft replacement
  • Pharmacological treatment

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Optimal time for pharmacological treatment of abdominal aortic aneurysm. / Iida, Yasunori; Sawa, Shigeharu; Shimizu, Hideyuki.

In: Current Drug Targets, Vol. 19, No. 11, 01.01.2018, p. 1297-1301.

Research output: Contribution to journalReview article

Iida, Yasunori ; Sawa, Shigeharu ; Shimizu, Hideyuki. / Optimal time for pharmacological treatment of abdominal aortic aneurysm. In: Current Drug Targets. 2018 ; Vol. 19, No. 11. pp. 1297-1301.
@article{f8c652f582df4f499e37df42f0ee965e,
title = "Optimal time for pharmacological treatment of abdominal aortic aneurysm",
abstract = "Background: Abdominal aortic aneurysm (AAA), if left untreated, poses the main risks of progressive expansion, rupture, and hemorrhage, leading to death. Large AAA with a risk of rupture is usually treated by graft replacement or endovascular aneurysm repair. Nonsurgical treatment is not an alternative for large AAA, but is potentially beneficial for small AAA which usually requires a watchful waiting approach with medication. Objective: We introduce current clinical research regarding the pharmacological treatment of small AAA and assess the optimal time for starting the treatment. Results: Data from current clinical researches on pharmacological treatment of AAA investigating the efficacy of pharmacological treatment to limit AAA growth were presented and introduced the medicines currently evaluated by randomized controlled trials for their efficacy for AAA. Conclusion: The optimal time to administer pharmacological treatment for AAA is during the stage wherein its diameter is still small. To detect early small-diameter AAA, screening tests are mandatory in high-risk patients. For pharmacological treatment, the drug that shows acceptable results in clinical tests and is the most effective for the patient’s condition should be carefully selected. Lifestyle changes should also accompany pharmacological treatment.",
keywords = "Abdominal aortic aneurysm, Cardiovascular surgery, Chronic inflammation, Endovascular aneurysm repair, Graft replacement, Pharmacological treatment",
author = "Yasunori Iida and Shigeharu Sawa and Hideyuki Shimizu",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1389450119666171227225008",
language = "English",
volume = "19",
pages = "1297--1301",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

TY - JOUR

T1 - Optimal time for pharmacological treatment of abdominal aortic aneurysm

AU - Iida, Yasunori

AU - Sawa, Shigeharu

AU - Shimizu, Hideyuki

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Abdominal aortic aneurysm (AAA), if left untreated, poses the main risks of progressive expansion, rupture, and hemorrhage, leading to death. Large AAA with a risk of rupture is usually treated by graft replacement or endovascular aneurysm repair. Nonsurgical treatment is not an alternative for large AAA, but is potentially beneficial for small AAA which usually requires a watchful waiting approach with medication. Objective: We introduce current clinical research regarding the pharmacological treatment of small AAA and assess the optimal time for starting the treatment. Results: Data from current clinical researches on pharmacological treatment of AAA investigating the efficacy of pharmacological treatment to limit AAA growth were presented and introduced the medicines currently evaluated by randomized controlled trials for their efficacy for AAA. Conclusion: The optimal time to administer pharmacological treatment for AAA is during the stage wherein its diameter is still small. To detect early small-diameter AAA, screening tests are mandatory in high-risk patients. For pharmacological treatment, the drug that shows acceptable results in clinical tests and is the most effective for the patient’s condition should be carefully selected. Lifestyle changes should also accompany pharmacological treatment.

AB - Background: Abdominal aortic aneurysm (AAA), if left untreated, poses the main risks of progressive expansion, rupture, and hemorrhage, leading to death. Large AAA with a risk of rupture is usually treated by graft replacement or endovascular aneurysm repair. Nonsurgical treatment is not an alternative for large AAA, but is potentially beneficial for small AAA which usually requires a watchful waiting approach with medication. Objective: We introduce current clinical research regarding the pharmacological treatment of small AAA and assess the optimal time for starting the treatment. Results: Data from current clinical researches on pharmacological treatment of AAA investigating the efficacy of pharmacological treatment to limit AAA growth were presented and introduced the medicines currently evaluated by randomized controlled trials for their efficacy for AAA. Conclusion: The optimal time to administer pharmacological treatment for AAA is during the stage wherein its diameter is still small. To detect early small-diameter AAA, screening tests are mandatory in high-risk patients. For pharmacological treatment, the drug that shows acceptable results in clinical tests and is the most effective for the patient’s condition should be carefully selected. Lifestyle changes should also accompany pharmacological treatment.

KW - Abdominal aortic aneurysm

KW - Cardiovascular surgery

KW - Chronic inflammation

KW - Endovascular aneurysm repair

KW - Graft replacement

KW - Pharmacological treatment

UR - http://www.scopus.com/inward/record.url?scp=85052217431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052217431&partnerID=8YFLogxK

U2 - 10.2174/1389450119666171227225008

DO - 10.2174/1389450119666171227225008

M3 - Review article

VL - 19

SP - 1297

EP - 1301

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 11

ER -